Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Cellular Plasticity, Epithelial-Mesenchymal Transition and Metastasis

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 3357

Share This Special Issue

Special Issue Editor

Prof. Dr. Martin Schreiber

E-Mail Website
Guest Editor

Department of Obstetrics & Gynecology, Medical University of Vienna, 1090 Vienna, Austria
Interests: breast cancer; diagnostic and prognostic markers; gene expression; transcriptional regulation; genomics and transcriptomics; p53 pathway; hormone receptor pathways; epithelial-mesenchymal transition
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Epithelial to mesenchymal transition (EMT) is a physiological transdifferentiation program by which epithelial cells undergo profound phenotypic and molecular changes to gradually lose their polarized epithelial morphology and expression of epithelial genes, specifically cell adhesion and epithelial polarity molecules. Instead, they acquire the fibroblastoid morphology, gene expression programs, and higher motility of mesenchymal cells. EMT plays crucial roles in embryogenesis and in the formation of the body plan. In addition, EMT can also be activated transiently or stably, and to different degrees, by epithelial cancer cells, which endows them with migratory, invasive, and cancer stem cell properties, increasing their resistance to apoptosis and chemotherapy in addition to enabling them to metastasize; however, aspects of EMT are also activated in non-epithelial cancer cells, as well as in fibrosis. EMT in development and cancer is typically regulated by several core transcription factors (SNAI1/2, ZEB1/2, and TWIST1), which are frequently upregulated in various combinations during EMT. Cancer cells often undergo partial rather than complete EMT, thus attaining a cellular phenotype along the epithelial–mesenchymal continuum and exhibiting both epithelial and mesenchymal properties. Partial EMT is thought to increase cellular plasticity and adaptability as well as invasive and metastatic capacity, whereas more complete EMT is thought to be associated with resistance to chemotherapy.

This Special Issue intends to bridge the gap between functional studies in in vitro and in vivo models of EMT and demonstrations of EMT in clinical (tumor) samples and their association with motility, invasiveness, metastasis, chemoresistance, and cancer cell stemness. Submissions of research articles and reviews covering all aspects of EMT, cellular plasticity, and/or metastasis are welcome.

Prof. Dr. Martin Schreiber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

epithelial–mesenchymal transition (EMT)
partial vs. full EMT
cellular plasticity
EMT in physiology and development
cancer
fibrosis
invasion and metastasis

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

23 pages, 5052 KiB

Open AccessArticle

Co-Expression Network Analysis Unveiled lncRNA-mRNA Links Correlated to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance and/or Intermediate Epithelial-to-Mesenchymal Transition Phenotypes in a Human Non-Small Cell Lung Cancer Cellular Model System

by Valentina Fustaino, Giuliana Papoff, Francesca Ruberti and Giovina Ruberti

Int. J. Mol. Sci. 2024, 25(7), 3863; https://doi.org/10.3390/ijms25073863 - 29 Mar 2024

Viewed by 739

Abstract

We investigated mRNA-lncRNA co-expression patterns in a cellular model system of non-small cell lung cancer (NSCLC) sensitive and resistant to the epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib/gefitinib. The aim of this study was to unveil insights into the complex mechanisms of NSCLC targeted therapy resistance and epithelial-to-mesenchymal transition (EMT). Genome-wide RNA expression was quantified for weighted gene co-expression network analysis (WGCNA) to correlate the expression levels of mRNAs and lncRNAs. Functional enrichment analysis and identification of lncRNAs were conducted on modules associated with the EGFR-TKI response and/or intermediate EMT phenotypes. We constructed lncRNA-mRNA co-expression networks and identified key modules and their enriched biological functions. Processes enriched in the selected modules included RHO (A, B, C) GTPase and regulatory signaling pathways, apoptosis, inflammatory and interleukin signaling pathways, cell adhesion, cell migration, cell and extracellular matrix organization, metabolism, and lipid metabolism. Interestingly, several lncRNAs, already shown to be dysregulated in cancer, are connected to a small number of mRNAs, and several lncRNAs are interlinked with each other in the co-expression network. Full article

(This article belongs to the Special Issue Cellular Plasticity, Epithelial-Mesenchymal Transition and Metastasis)

► Show Figures

Figure 1

14 pages, 9656 KiB

Open AccessArticle

Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial–Mesenchymal Transition and Stemness Properties

by Feng-Che Kuan, Jhy-Ming Li, Yun-Ching Huang, Shun-Fu Chang and Chung-Sheng Shi

Int. J. Mol. Sci. 2023, 24(24), 17610; https://doi.org/10.3390/ijms242417610 - 18 Dec 2023

Viewed by 1108

Abstract

Bladder cancer is becoming one of the most common malignancies across the world. Although treatment strategy has been continuously improved, which has led to cisplatin-based chemotherapy becoming the standard medication, cancer recurrence and metastasis still occur in a high proportion of patients because of drug resistance. The high efficacy of regorafenib, a broad-spectrum kinase inhibitor, has been evidenced in treating a variety of advanced cancers. Hence, this study investigated whether regorafenib could also effectively antagonize the survival of cisplatin-resistant bladder cancer and elucidate the underlying mechanism. Two types of cisplatin-resistant bladder cancer cells, T24R1 and T24R2, were isolated from T24 cisplatin-sensitive bladder cancer cells. These cells were characterized, and T24R1- and T24R2-xenografted tumor mice were created to examine the therapeutic efficacy of regorafenib. T24R1 and T24R2 cells exhibited higher expression levels of epithelial–mesenchymal transition (EMT) and stemness markers compared to the T24 cells, and regorafenib could simultaneously inhibit the viability and the expression of EMT/stemness markers of both T24R1 and T24R2 cells. Moreover, regorafenib could efficiently arrest the cell cycle, promote apoptosis, and block the transmigration/migration capabilities of both types of cells. Finally, regorafenib could significantly antagonize the growth of T24R1- and T24R2-xenografted tumors in mice. These results demonstrated the therapeutic efficacy of regorafenib in cisplatin-resistant bladder cancers. This study, thus, provides more insights into the mechanism of action of regorafenib and demonstrates its great potential in the future treatment of cisplatin-resistant advanced bladder cancer patients. Full article

(This article belongs to the Special Issue Cellular Plasticity, Epithelial-Mesenchymal Transition and Metastasis)

► Show Figures

Graphical abstract

Review

Jump to: Research

22 pages, 1308 KiB

Open AccessReview

Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases

by Dureali Mirjat, Muhammad Kashif and Cai M. Roberts

Int. J. Mol. Sci. 2023, 24(24), 17539; https://doi.org/10.3390/ijms242417539 - 16 Dec 2023

Viewed by 1104

Abstract

TWIST1 is a transcription factor that is necessary for healthy neural crest migration, mesoderm development, and gastrulation. It functions as a key regulator of epithelial-to-mesenchymal transition (EMT), a process by which cells lose their polarity and gain the ability to migrate. EMT is often reactivated in cancers, where it is strongly associated with tumor cell invasion and metastasis. Early work on TWIST1 in adult tissues focused on its transcriptional targets and how EMT gave rise to metastatic cells. In recent years, the roles of TWIST1 and other EMT factors in cancer have expanded greatly as our understanding of tumor progression has advanced. TWIST1 and related factors are frequently tied to cancer cell stemness and changes in therapeutic responses and thus are now being viewed as attractive therapeutic targets. In this review, we highlight non-metastatic roles for TWIST1 and related EMT factors in cancer and other disorders, discuss recent findings in the areas of therapeutic resistance and stemness in cancer, and comment on the potential to target EMT for therapy. Further research into EMT will inform novel treatment combinations and strategies for advanced cancers and other diseases. Full article

(This article belongs to the Special Issue Cellular Plasticity, Epithelial-Mesenchymal Transition and Metastasis)

► Show Figures